Expression of p-27 (kip1) in nevi and melanomas

American Journal of Dermatopathology

Volumn 21, Issue 2, 1999, Pages 121-124

  Morgan, Michael B ^a,b,c   Cowper, Shawn E ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Ameripath/Derrick and Associates   (United States)

Author keywords

Compound nevi; Melanoma; p27 (kip1); Spitz nevi

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P27;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CELL NUCLEUS; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEVUS; NEVUS, EPITHELIOID AND SPINDLE CELL; SKIN; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 0032907890     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000372-199904000-00002     Document Type: Article

References (23)

1. Hunter T, Pines J. Cyclins and cancer 2: cyclin D and inhibitors come of age. Cell 1994;79:573-82.
2. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79: 551-5.
3. King RW, Jackson PK, Kirschner MW. Mitosis in transition. Cell 1994;79:563-71.
4. Reed SI, Bailley E, Dulic V, Hengst L, et al. G1 control in mammalian cells. J Cell Sci 1994;18(suppl):69-73.
5. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
6. Clurman B, Roberts J. Cell cycle and cancer. J Natl Cancer Inst 1995;87:1499-501.
7. Ferrando AA, Balbin M, Pendas AM, et al. Mutational analysis of the human cyclin dependent kinase inhibitor p27 in primary breast carcinoma. Hum Genet 1996;97:91-4.
8. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
9. Hengst L, Reed S. Translational control of p27 accumulation during the cell cycle. Science 1995;269:1861-4.
10. Polyak K, Kato JV, Soloman MF, Sherr CS, et al. p27, a cyclin-CDK inhibitor, links TGF-B and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22.
11. Koff A, Ohtsuki M, Polyak K, Roberts JM, et al. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-B. Science 1993;260:536-9.
12. Coats S, Flannagan W, Nourse J, Roberts J. Requirement of p27 for restriction point control of the fibroblast cell cycle. Science 1996;272:877-80.
13. Nourse J, Firpo E, Flannagan W, et al. Interleukin-2 mediated elimination of p27 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372:570-3.
14. Qian X, Lin L, Grade JP, Lloyd RV. TGF-B and p27 expression in pituitary cells. Endocrinology 1996;137:3051-60.
15. Lloyd RV, Jin L, Qian X, Kulig E. Aberrant p27 expression in endocrine and other tumors. Am J Pathol 1997;150:401-7.
16. Erickson LA, Jin L. Wollan PC, et al. Expression of p27 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 1998;11: 169-74.
17. Catzavelos C, Bhattachara N, Ung YC, et al. Decreased levels of cell cycle inhibitor p27 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
18. Porter P, Malone KE, Heagerty PJ, et al. Expression of cell cycle regulators p27 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3: 222-4.
19. Loda M, Cukor B, Tam SW, et al. Increased proteosome-dependent degradation of the cyclin-dependent inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
20. Ackerman AB. Clues to diagnosis in dermatopathology. Chicago: ASCP Press, 1993.
21. Smith KJ, Barrett TL, Smith WF, Skelton MM. A review of tumor suppressor genes in cutaneous neoplasms with emphasis on cell cycle regulators. Am J Dermatopathol 1998;20:302-13.
22. Moretti S, Pinzi C, Berti E, et al. In-situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki-67, HLA-DR, and beta 3 integrin expression. Melanoma Res 1997;7:313-21.
23. Van Belle P, Rodeck V, Nuamah I, Halpern AC. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 1996;148:1887-94.